What is the P/E ratio of PainChek 2024?
The P/E ratio cannot be calculated for PainChek at the moment.
Own the gold standard ✨ in financial data & analytics
Subscribe for $2 
Overview
Profile
PainChek Stock stock price, forecast, news, chart, split, dividend and analysis PainChek ariva, PainChek onvista, PainChek finanzen.net, PainChek aktienfinder, PainChek marketscreener, PainChek marketwatch, PainChek bloomberg, PainChek handelsblatt, PainChek wiwo, PainChek forum
PCK.AX
AU000000PCK6
Price
Price
0.03
Today +/-
+0
Today %
+0 %
TickerPCK.AX
ISINAU000000PCK6
P
PainChek Revenue, EBIT, Net Income AU000000PCK6 ·
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into PainChek, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by PainChek from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects PainChek’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of PainChek. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into PainChek’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing PainChek’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on PainChek’s growth potential.
PainChek Revenue, EBIT and net profit per share
| Date | PainChek Revenue | PainChek EBIT | PainChek Net Income |
|---|---|---|---|
| 2023 | 1.96 M undefined | -7.57 M undefined | -7.57 M undefined |
| 2022 | 994,150 undefined | -5.72 M undefined | -5.72 M undefined |
| 2021 | 233,890 undefined | -6.06 M undefined | -6.06 M undefined |
| 2020 | 297,180 undefined | -12.39 M undefined | -12.39 M undefined |
| 2019 | 215,460 undefined | -3.26 M undefined | -3.26 M undefined |
| 2018 | 50,650 undefined | -3.1 M undefined | -4.81 M undefined |
| 2017 | 31,120 undefined | -3.9 M undefined | -8.47 M undefined |
| 2016 | 600 undefined | -1.41 M undefined | -5.05 M undefined |
| 2015 | 550 undefined | -911,350 undefined | -1.7 M undefined |
| 2014 | 10,000 undefined | -700,000 undefined | -790,000 undefined |
| 2013 | 60,000 undefined | -800,000 undefined | -1.1 M undefined |
| 2012 | 20,000 undefined | -410,000 undefined | -410,000 undefined |
| 2011 | 0 undefined | -40,000 undefined | -40,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2011 | 0 AUD | -40,000 AUD | -40,000 AUD |
| 2012 | 20,000 AUD | -410,000 AUD | -410,000 AUD |
| 2013 | 60,000 AUD | -800,000 AUD | -1.1 M AUD |
| 2014 | 10,000 AUD | -700,000 AUD | -790,000 AUD |
| 2015 | 550 AUD | -911,350 AUD | -1.7 M AUD |
| 2016 | 600 AUD | -1.41 M AUD | -5.05 M AUD |
| 2017 | 31,120 AUD | -3.9 M AUD | -8.47 M AUD |
| 2018 | 50,650 AUD | -3.1 M AUD | -4.81 M AUD |
| 2019 | 215,460 AUD | -3.26 M AUD | -3.26 M AUD |
| 2020 | 297,180 AUD | -12.39 M AUD | -12.39 M AUD |
| 2021 | 233,890 AUD | -6.06 M AUD | -6.06 M AUD |
| 2022 | 994,150 AUD | -5.72 M AUD | -5.72 M AUD |
| 2023 | 1.96 M AUD | -7.57 M AUD | -7.57 M AUD |
PainChek Stock Ratios
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,000 |
| - | - | - | - | - | - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | - | - |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | -1 | -3 | -3 | -3 | -12 | -6 | -5 | -7 |
| - | - | - | - | - | - | - | - | - | - | - | - | -700.00 |
| 0 | 0 | -1 | 0 | -1 | -5 | -8 | -4 | -3 | -12 | -6 | -5 | -7 |
| - | - | - | - | - | 400.00 | 60.00 | -50.00 | -25.00 | 300.00 | -50.00 | -16.67 | 40.00 |
| 0.02 | 0.02 | 0.02 | 0.02 | 0.04 | 0.14 | 0.52 | 0.8 | 0.84 | 0.99 | 1.12 | 1.14 | 1.29 |
| - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The PainChek Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the PainChek is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
PainChek stock margins AU000000PCK6 ·
The PainChek margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PainChek. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PainChek.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the PainChek's sales revenue. A higher gross margin percentage indicates that the PainChek retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the PainChek's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the PainChek's total revenue generated. When comparing the revenue margin year over year, investors can gauge the PainChek's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the PainChek. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the PainChek's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
PainChek Margin History
| PainChek Gross margin | PainChek Profit margin | PainChek EBIT margin | PainChek Profit margin |
|---|---|---|---|
| 2023 | 36.75 % | -387.28 % | -387.28 % |
| 2022 | -24.47 % | -575.42 % | -575.42 % |
| 2021 | -173.21 % | -2,592.52 % | -2,592.52 % |
| 2020 | 10.77 % | -4,170.08 % | -4,170.09 % |
| 2019 | 36.75 % | -1,514.17 % | -1,514.17 % |
| 2018 | 36.75 % | -6,122.45 % | -9,497.59 % |
| 2017 | 36.75 % | -12,533.45 % | -27,229.43 % |
| 2016 | 36.75 % | -234,474.98 % | -841,241.6 % |
| 2015 | 36.75 % | -165,700 % | -309,769.1 % |
| 2014 | 36.75 % | -7,000 % | -7,900 % |
| 2013 | 36.75 % | -1,333.33 % | -1,833.33 % |
| 2012 | 36.75 % | -2,050 % | -2,050 % |
| 2011 | 36.75 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2011 | 36.75 % | 0 % | 0 % |
| 2012 | 36.75 % | -2,050 % | -2,050 % |
| 2013 | 36.75 % | -1,333.33 % | -1,833.33 % |
| 2014 | 36.75 % | -7,000 % | -7,900 % |
| 2015 | 36.75 % | -165,700 % | -309,769.1 % |
| 2016 | 36.75 % | -234,474.98 % | -841,241.6 % |
| 2017 | 36.75 % | -12,533.45 % | -27,229.43 % |
| 2018 | 36.75 % | -6,122.45 % | -9,497.59 % |
| 2019 | 36.75 % | -1,514.17 % | -1,514.17 % |
| 2020 | 10.77 % | -4,170.08 % | -4,170.09 % |
| 2021 | -173.21 % | -2,592.52 % | -2,592.52 % |
| 2022 | -24.47 % | -575.42 % | -575.42 % |
| 2023 | 36.75 % | -387.28 % | -387.28 % |
PainChek Stock Sales Revenue, EBIT, Earnings per Share AU000000PCK6 ·
The PainChek earnings per share therefore indicates how much revenue PainChek has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue PainChek earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates PainChek's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of PainChek’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PainChek's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
PainChek Revenue, EBIT and net profit per share
| Date | PainChek Sales per Share | PainChek EBIT per share | PainChek Earnings per Share |
|---|---|---|---|
| 2023 | 0 undefined | -0.01 undefined | -0.01 undefined |
| 2022 | 0 undefined | -0 undefined | -0 undefined |
| 2021 | 0 undefined | -0.01 undefined | -0.01 undefined |
| 2020 | 0 undefined | -0.01 undefined | -0.01 undefined |
| 2019 | 0 undefined | -0 undefined | -0 undefined |
| 2018 | 0 undefined | -0 undefined | -0.01 undefined |
| 2017 | 0 undefined | -0.01 undefined | -0.02 undefined |
| 2016 | 0 undefined | -0.01 undefined | -0.04 undefined |
| 2015 | 0 undefined | -0.02 undefined | -0.04 undefined |
| 2014 | 0 undefined | -0.04 undefined | -0.04 undefined |
| 2013 | 0 undefined | -0.04 undefined | -0.06 undefined |
| 2012 | 0 undefined | -0.02 undefined | -0.02 undefined |
| 2011 | 0 undefined | -0 undefined | -0 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2011 | 0 AUD | -0 AUD | -0 AUD |
| 2012 | 0 AUD | -0.02 AUD | -0.02 AUD |
| 2013 | 0 AUD | -0.04 AUD | -0.06 AUD |
| 2014 | 0 AUD | -0.04 AUD | -0.04 AUD |
| 2015 | 0 AUD | -0.02 AUD | -0.04 AUD |
| 2016 | 0 AUD | -0.01 AUD | -0.04 AUD |
| 2017 | 0 AUD | -0.01 AUD | -0.02 AUD |
| 2018 | 0 AUD | -0 AUD | -0.01 AUD |
| 2019 | 0 AUD | -0 AUD | -0 AUD |
| 2020 | 0 AUD | -0.01 AUD | -0.01 AUD |
| 2021 | 0 AUD | -0.01 AUD | -0.01 AUD |
| 2022 | 0 AUD | -0 AUD | -0 AUD |
| 2023 | 0 AUD | -0.01 AUD | -0.01 AUD |
PainChek business model
PainChek is one of the most popular companies on Eulerpool.com.
PainChek valuation based on historical P/E ratio, EBIT, and P/S ratio.
PainChek shares outstanding AU000000PCK6 ·
The number of shares was PainChek in 2023 — This indicates how many shares 1.29 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue PainChek earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates PainChek's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of PainChek’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PainChek's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2011 | 18.64 M Aktien |
| 2012 | 18.64 M Aktien |
| 2013 | 18.02 M Aktien |
| 2014 | 18.49 M Aktien |
| 2015 | 41.1 M Aktien |
| 2016 | 135.01 M Aktien |
| 2017 | 521.02 M Aktien |
| 2018 | 803.51 M Aktien |
| 2019 | 841.09 M Aktien |
| 2020 | 992.34 M Aktien |
| 2021 | 1.12 B Aktien |
| 2022 | 1.14 B Aktien |
| 2023 | 1.29 B Aktien |
PainChek Stock splits
In PainChek's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for PainChek.
PainChek Stock Shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 7.25 % | Peters Investments Pty. Ltd. | 118,650,000 | 0 | 10/18/2023 |
| 2.32 % | J & E Consulting Pty. Ltd. | 38,003,125 | 0 | 10/18/2023 |
| 2.31 % | Hoti (Kreshnik) | 37,717,411 | 0 | 10/18/2023 |
| 2.26 % | Atee (Mustafa Abdul Wahed) | 37,003,125 | 0 | 10/18/2023 |
| 1.55 % | Daffas (Philip) | 25,310,946 | 1,193,793 | 3/11/2024 |
| 1.41 % | Williamson (Craig Robert) | 23,138,234 | 3,882,551 | 10/18/2023 |
| 1.19 % | G & G Chilcott Pty. Ltd. | 19,482,725 | 5,555,556 | 10/18/2023 |
| 1.04 % | Murray (John) | 17,011,439 | 397,931 | 3/11/2024 |
| 0.97 % | Stevens Family Super Fund | 15,802,500 | 0 | 10/18/2023 |
| 0.95 % | Piperlake Pty. Ltd. | 15,600,322 | 15,600,322 | 10/18/2023 |
1
2
PainChek Executives and Management Board
Mr. Philip Daffas
PainChek Managing Director, Director (since 2016)
Compensation 410,583
Mr. Iain McAdam
PainChek Chief Financial Officer
Compensation 393,165
Mr. John Murray
PainChek Non-Executive Chairman of the Board
Compensation 94,995
Mr. Adam Davey
PainChek Non-Executive Director
Compensation 47,498
Mr. Ross Harricks
PainChek Non-Executive Director
Compensation 47,498
1
2
PainChek stock: Frequently Asked Questions
What is the P/S ratio of PainChek 2024?
The P/S cannot be calculated for PainChek currently.
What is the AlleAktien quality score of PainChek?
The AlleAktien quality score for PainChek is 6/10.
What is the revenue of PainChek 2024?
The revenue cannot currently be calculated for PainChek.
How high is the profit of PainChek 2024?
The profit cannot currently be calculated for PainChek.
What is the business model of PainChek
No history available for PainChek.
What is the PainChek dividend?
PainChek pays a dividend of 0 AUD distributed over payouts per year.
How often does PainChek pay dividends?
The dividend cannot currently be calculated for PainChek or the company does not pay out a dividend.
What is the PainChek ISIN?
The ISIN of PainChek is AU000000PCK6.
What is the PainChek ticker?
The ticker of PainChek is PCK.AX.
How much dividend does PainChek pay?
Over the past 12 months, PainChek paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PainChek is expected to pay a dividend of 0 AUD.
What is the dividend yield of PainChek?
The current dividend yield of PainChek is .
When does PainChek pay dividends?
PainChek pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of PainChek?
PainChek paid dividends every year for the past 0 years.
What is the dividend of PainChek?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is PainChek located?
PainChek is assigned to the 'Health' sector.
Wann musste ich die Aktien von PainChek kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of PainChek from 7/10/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 7/10/2024.
When did PainChek pay the last dividend?
The last dividend was paid out on 7/10/2024.
What was the dividend of PainChek in the year 2023?
In the year 2023, PainChek distributed 0 AUD as dividends.
In which currency does PainChek pay out the dividend?
The dividends of PainChek are distributed in AUD.
PainChek stock price, news, forecast, analysis
Sector
Health
Industry
Health Care Technology
Number of shares
Employee
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Country
Australia 🇦🇺
Currency
AUD
Initial public offering
May 1, 2012
GOSIN
Global Open Securities Identification Number
Cusip
Q7S247103
Market capitalization
PEG
0
P/E
Forward P/E
0
P/S
Forward P/S
0
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC
Scalable Capital savings plan Nein
Trade Republic savings plan Nein
comdirect savings plan
Consorsbank savings plan Nein
ING savings plan Nein
PainChek Peer Group
PainChek Eulerpool News
PainChek News
PainChek FIGI
| PainChek Ticker | PainChek FIGI |
|---|---|
| PCK:AU | BBG002N7WGG6 |
| PCK:AT | BBG002N7WGH5 |
| PCK:AH | BBG002N7WGM9 |
Other fundamentals and analyses of PainChek in the deep dive.
Our stock analysis for PainChek Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PainChek Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.